Clinical Care Considerations for COVID-19 Vaccination

The Advisory Committee on Immunization Practices (ACIP) has issued interim recommendations for the use of Pfizer-BioNTech, Moderna, ​and Janssen/Johnson & Johnson COVID-19 vaccines for the prevention of coronavirus disease 2019 (COVID-19) in the United States. You can find these recommendations as well as clinical considerations for managing adverse events below.

Use of COVID-19 Vaccines

Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States.

Phased Implementation and Sub-Prioritization

Interim considerations for phased implementation of COVID-19 vaccination and sub-prioritization among recommended populations.

Vaccinating Special Populations
Page last reviewed: March 11, 2021